These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37978096)

  • 1. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
    Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
    Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Ebell MH; Barry HC; Baduni K; Grasso G
    Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.
    Lacorte E; Ancidoni A; Zaccaria V; Remoli G; Tariciotti L; Bellomo G; Sciancalepore F; Corbo M; Lombardo FL; Bacigalupo I; Canevelli M; Piscopo P; Vanacore N
    J Alzheimers Dis; 2022; 87(1):101-129. PubMed ID: 35275549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
    Menegaz de Almeida A; Leite M; Lopes LM; Gomes Lima P; Siegloch Barros ML; Rocha Pinheiro S; Andrade Í; Viana P; Morbach V; Marinheiro G; de Oliveira R; Pinheiro AC
    Expert Rev Neurother; 2024 Sep; 24(9):929-936. PubMed ID: 38879828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
    Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
    Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
    Qiao Y; Chi Y; Zhang Q; Ma Y
    Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis.
    Li C; Ma Q; Chen S; Feng J; He Y
    Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(4):83-7. PubMed ID: 27188740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Penninkilampi R; Brothers HM; Eslick GD
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):194-203. PubMed ID: 28025724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Abushouk AI; Elmaraezy A; Aglan A; Salama R; Fouda S; Fouda R; AlSafadi AM
    BMC Neurol; 2017 Apr; 17(1):66. PubMed ID: 28376794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.